Related Experiment Videos
EGF-grafted PDMS surfaces in artificial cornea applications.
B J Klenkler1, M Griffith, C Becerril
1Department of Chemical Engineering, McMaster University, Hamilton, ON, Canada L8S 4L7.
Biomaterials
|July 16, 2005
Summary
Modifying artificial cornea surfaces with epidermal growth factor (EGF) improved corneal epithelial cell coverage. Covalently bound EGF on polydimethylsiloxane (PDMS) surfaces actively promoted cell growth, addressing a key challenge in artificial cornea design.
Area of Science:
- Biomaterials Science
- Ophthalmology
- Tissue Engineering
Background:
- Artificial cornea design faces challenges with epithelial cell coverage.
- Polydimethylsiloxane (PDMS) is a common material for artificial corneas.
- Enhancing cell adhesion and proliferation is crucial for artificial cornea integration.
Purpose of the Study:
- To modify PDMS surfaces with epidermal growth factor (EGF) to promote corneal epithelial cell growth.
- To investigate the efficacy of covalently bound EGF on PDMS substrates.
- To improve epithelial cell coverage on artificial cornea materials.
Main Methods:
- PDMS surfaces were modified with EGF using allylamine plasma polymerization and a polyethylene glycol (PEG) spacer.
- Surface modification was verified using contact angle and X-ray photoelectron spectroscopy.
- Epidermal growth factor (EGF) immobilization density was quantified using surface plasmon resonance (SPR) and radiolabelling.
- Human corneal epithelial cells were cultured on modified and unmodified surfaces.
Main Results:
- Covalently tethered EGF on PDMS surfaces was confirmed to be biologically active.
- Modified surfaces demonstrated significantly improved corneal epithelial cell coverage compared to controls.
- The density of bound EGF influenced the degree of cell coverage.
Conclusions:
- Surface modification of PDMS with covalently bound EGF effectively promotes corneal epithelial cell coverage.
- This approach offers a promising strategy for improving the performance of artificial corneas.
- Active, surface-bound growth factors can enhance the biocompatibility of implantable devices.